Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0044-1786001
In Response

Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study

Soumya Simhadri
1   Department of Oncology, Soumya Multispecialty Hospital, Secunderabad, Telangana, India
,
Sowmya Dayyala
1   Department of Oncology, Soumya Multispecialty Hospital, Secunderabad, Telangana, India
,
Anjani Devi Musinipally
2   Department of Oncology, Osmania Medical College, Hyderabad, Telangana, India
,
Lavanya Guram
1   Department of Oncology, Soumya Multispecialty Hospital, Secunderabad, Telangana, India
,
Mamatha Madavi
1   Department of Oncology, Soumya Multispecialty Hospital, Secunderabad, Telangana, India
,
Ramakrishna Kancha
3   Department of Oncology, Osmania University, Hyderabad, Telangana, India
,
Krishna Chaitanya Puligundla
4   Department of Oncology, MNJ Institute of Oncology, Hyderabad, Telangana, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Zoom Image
Krishna Chaitanya Puligundla

Chemotherapy-induced nausea and vomiting (CINV) is a challenging adverse effect that is associated with deteriorating quality of life. Inhibiting neurokinin 1 and 5-hydroxytryptamine type 3 receptors involved in the major emesis pathways has significantly prevented CINV and is recommended as standard treatment in international antiemetic guidelines. This retrospective study was conducted to explore the efficacy of formulated netupitant (NE; 300 mg) and palonosetron (PA; 0.50mg) tablets with dexamethasone in patients receiving high and moderate emetogenic chemotherapy. A single dose of NE, PA, and dexamethasone was given 1 hour prior to the chemotherapy for 4 days. The key end-points were to assess complete response (CR), complete protection (CP), and complete control (CC) with no emesis, no nausea, and no use of rescue medication during acute (0–24 hours) and delayed phase (24–120 hours) of CINV. This study conducted on 212 patients showed overall rates of CR, CP, and CC as 97.5, 91.1, and 92.19%, respectively, in the acute phase and 95.09, 88.06, and 87.74% in a delayed phase. These patients underwent 1,387 cycles of chemotherapy involving both high emetogenic chemotherapy and moderate emetogenic chemotherapy regimens. A decrease in the rate of CR, CP, and CC from 93.47, 76.20, and 73.90% (acute phase) to 86.95, 69.67, and 67.37% (delayed phase) with highly emetogenic chemotherapy was observed, while the combination treatment achieved 100 CR, CP, and CC in both the acute and delayed phase with the moderately emetogenic chemotherapy regimen. Our study demonstrated the promising efficacy of the triple treatment with formulated NE and PA tablets in combination with dexamethasone in preventing and managing CINV in real-world settings.

Keywords

chemotherapy-induced nausea and vomiting - emetogenic chemotherapy - NK 1 receptor antagonist - 5-HT3 receptor antagonists - NEPA

Authors' Contribution

All the authors contributed equally to the conception and design of the study, acquisition of data, drafting of the article or revising it critically for important intellectual content, and final approval of the version to be submitted.




Publication History

Received: 18 October 2023

Accepted: 20 March 2024

Article published online:
15 April 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Di Renzo N, Musso M, Scimè R. et al. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant 2020; 55 (11) 2114-2120
    CrossrefPubMedGoogle Scholar
  • 2 Aapro M, Jordan K, Scotté F, Celio L, Karthaus M, Roeland E. Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Curr Cancer Drug Targets 2022; 22 (10) 806-824
    CrossrefPubMedGoogle Scholar
  • 3 Grunberg SM, Slusher B, Rugo HS. Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2013; 11 (2 Suppl 1): 1-18
    PubMedGoogle Scholar
  • 4 Aapro M, Karthaus M, Schwartzberg L. et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer 2017; 25 (04) 1127-1135
    CrossrefPubMedGoogle Scholar
  • 5 Karthaus M, Oskay-Özcelik G, Wülfing P. et al. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life. Future Oncol 2020; 16 (14) 939-953
    CrossrefPubMedGoogle Scholar
  • 6 Vaswani B, Dattatreya PS, Bhagat S, Patil S, Barkate H. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting. BMC Cancer 2021; 21 (01) 601
    CrossrefPubMedGoogle Scholar
  • 7 Aapro M, Rugo H, Rossi G. et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25 (07) 1328-1333
    CrossrefPubMedGoogle Scholar
  • 8 Schwartzberg LS, Marks SM, Gabrail NY, Geller RB, Kish J. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting. J Comp Eff Res 2019; 8 (09) 657-670
    CrossrefPubMedGoogle Scholar
  • 9 Recupero A. Novel Formulations to Improve the Control of Emesis [Internet]. Accessed March 28, 2024 at: www.AptalisPharmaceuticalTechnologies.com/
    Google Scholar
  • 10 Roila F, Molassiotis A, Herrstedt J. et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (Suppl. 05) v119-v133
    CrossrefPubMedGoogle Scholar
  • 11 Hesketh PJ, Kris MG, Basch E. et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35 (28) 3240-3261
    CrossrefPubMedGoogle Scholar
  • 12 Giuliano C, Lovati E, Funk C, Potthast M, Pietra C. In vitro drug-drug interaction studies with the antiemetic drug netupitant and its major metabolites M1 and M2, involving several human cytochrome P450 isoenzymes. Ann Oncol 2012; 23: ix520
    CrossrefGoogle Scholar
  • 13 Zelek L, Debourdeau P, Bourgeois H. et al. A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Oncologist 2021; 26 (10) e1870-e1879
    CrossrefPubMedGoogle Scholar
  • 14 Hesketh PJ, Rossi G, Rizzi G. et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25 (07) 1340-1346
    CrossrefPubMedGoogle Scholar
  • 15 Zhang L, Lu S, Feng J. et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 2018; 29 (02) 452-458
    CrossrefPubMedGoogle Scholar
  • 16 Conter H, Mithoowani H, Prady C, Gupta R, Khodadad K. A phase IV, real world observational study on the use of netupitant/palonosetron (NEPA®) for the prevention of CINV in patients receiving highly emetogenic chemotherapy (HEC) over multiple cycles. J Oncol Pharm. 2020; 26 (04) 18-19
    Google Scholar
  • 17 Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits 2012; 5 (04) 232-240
    PubMedGoogle Scholar
  • 18 Rochester MP, Kane AM, Linnebur SA, Fixen DR. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. Ther Adv Drug Saf 2018; 9 (06) 297-308
    CrossrefPubMedGoogle Scholar